OBJECTIVE:
In 2016, the American College of Obstetricians and Gynecologists and the Society for Maternal Fetal Medicine released guidance supporting the use of late preterm steroids. Our goal was to evaluate antenatal steroid use subsequent to these guidelines. STUDY DESIGN: This cohort study used chart-abstracted data on term consecutive births occurring in 2017 at 16 hospitals in the Northwest region of the United States. The rate of newborn exposure to antenatal steroids was calculated for early preterm (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) +6 weeks) and late preterm births (34-36 +6 weeks). Eligibility for late preterm steroids included singleton gestation, no exposure to steroids prior to 34 weeks gestation, and no maternal pre-pregnancy diabetes. The rate of late preterm steroid use within and outside the national guidelines was calculated. The percentage of late preterm newborns who were exposed to steroids was stratified by gestational week at birth. Use of late preterm steroids was examined by hospital level of neonatal care.
RESULTS:
The study population compromised 27,524 births, of which 2.9% were early preterm and 7.1% late preterm. Six percent (n¼1655) of newborns were exposed to antenatal steroids including 1.9% (n¼530) in the late preterm period. Of 530 exposed to late preterm steroids, 20.2% had one or more guideline-endorsed exclusion to their use, 17.2% delivered at term and 16.6% were born on the same day as steroids were given. (Table 1 ) Overall, 25.7% of guideline -eligible late preterm newborns were exposed to late preterm steroids and use varied with gestational age. (Figure 1) 
